Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.9074 +0.0065 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen Inc

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
33 34 Next >
WHO To Decide On EUL Of Ocugen-Partnered COVID-19 Vaccine Today
An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today. Covaxin is India's indigenously-... 
Via Benzinga
Exposures COVID-19
Ocugen Stock Just Needs a Catalyst to Break Free
OCGN stock holders should be patient as the World Health Organization's potential approval of an important vaccine could happen soon. 
Via InvestorPlace
Exposures COVID-19
It’s Time To Drop Ocugen Stock While You Still Can
Hope is one thing, but for OCGN stock investors expecting regulators or other bulls to come to the rescue, things are starting to look gloomy. 
Via InvestorPlace
Ocugen Still Lacks a Path to U.S. Profits
Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources
The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin?
An anticipated emergency use listing for the vaccine won't help Ocugen. 
Via The Motley Fool
Exposures COVID-19
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
India-based Bharat Biotech has completed the Phase 2 and 3 trials of COVID-19 vaccine, Covaxin, for use in 2 to 18 years. Ocugen Inc (NASDAQ: OCGN... 
Via Benzinga
Exposures COVID-19
It’s OK to Sell the News on Ocugen and Covaxin
OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news. 
Via InvestorPlace
Could This News Spark a Turnaround for Ocugen?
Ocugen shares soared more than 700% early in the year. They've since lost half of the gain. 
Via The Motley Fool
Exposures COVID-19
Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision. 
Via The Motley Fool
Exposures COVID-19
I’d Take Nio Stock’s 12-Month Double Despite Falling Below $50
A $10,000 investment in NIO stock a year ago is worth more than $20,000 today. From here, under $40 remains a great entry point if you want to make money over the long haul. 
Via InvestorPlace
Topics Electric Vehicles
Exposures Electric Vehicles
WHO Approval Should Get Ocugen Stock Over the $15 Barrier
Sharp up-and-down moves in OCGN stock shouldn't scare investors away, as a regulator's nod for Covaxin should put the stock back on track. 
Via InvestorPlace
Here’s What the Charts Say About Ocugen Stock Now
Ocugen is a high-risk, high-reward speculative play. The charts for OCGN stock show some promise, but here's the level it has to hold above. 
Via InvestorPlace
OCGN Stock: Why Ocugen Shares Are Shooting Higher Today
The WHO could be about to green light a vaccine from one of Ocugen's partners, but that doesn't mean OCGN stock will stay in the green. 
Via InvestorPlace
72 Biggest Movers From Yesterday
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
Where's Ocugen Stock Headed Monday And Why?
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization.... 
Via Benzinga
Exposures COVID-19
Here's Why Ocugen Is Skyrocketing Today
There's both good and bad news for this troubled coronavirus vaccine biotech. 
Via The Motley Fool
Exposures COVID-19
OCGN Stock: What Ocugen Investors Are Saying as Shares Surge Today
Ocugen (OCGN) stock is on the move today as traders on social media push the company higher in a new rally for the shares. 
Via InvestorPlace
Why Are Ocugen Shares Surging On Monday?
According to sources, the World Health Organization (WHO) is likely to grant India's COVID-19 vaccine, Covaxin, for an emergency use listing (EUL) this week. Ocugen Inc... 
Via Benzinga
Exposures COVID-19
45 Stocks Moving In Monday's Mid-Day Session
Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)... 
Via Benzinga
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN
From Kahn Swick & Foti, LLC
Via Business Wire
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play. 
Via InvestorPlace
Exposures COVID-19
This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla
An investment in Ocugen Inc (NASDAQ: OCGN) one year ago is undoubtedly a sight for sore eyes. Since January 2021, Ocugen stock's year-to-date return has outperformed a number... 
Via Benzinga
Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved
There's no revenue yet for Ocugen, but OCGN stock could be worth 19% higher if its Covid-19 vaccine gets the thumbs up. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Will Suffer Its Inevitable Demise Sooner Rather Than Later
At some point, the music will stop for OCGN stock, but for now, there's still plenty at play to keep it at inflated prices. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Seems Unattractive With Regulatory Uncertainties
OCGN stock is unattractive as regulatory approval delays have limited the revenue and cash flow potential for the Covid-19 vaccine. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Doesn’t Have Short-Term Catalysts Needed To Make It a Buy
OCGN stock is interesting once again as concerns regarding the Delta variant mount. But that should not be your sole reason to invest in Ocugen. 
Via InvestorPlace
Exposures COVID-19
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now
ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution. 
Via InvestorPlace
The Odds Are Firmly Against Ocugen Stock Now
OCGN stock is a remarkably risky Covid-19 vaccine play, as the company faces a myriad of regulatory roadblocks on different fronts. 
Via InvestorPlace
Exposures COVID-19 Product Safety
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.